PDS and Spectrum rise, while Black Diamond, Alpine, Harpoon and Macrogenics disappoint, and others ride on big pharma’s coattails.
A handful of small caps, including Sensei and PDS, jumped on Asco abstract data, with much more news to come.
Key catalysts approach for Orphazyme, Gemini and Immutep.
Competing folate receptor-targeting projects have recorded one failure after another, but Sutro scores a phase I win.
As doubts grow about targeting the folate receptor, Immunogen’s decision to press on with mirvetuximab soravtansine looks desperate.